Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial
Open Access
- 6 July 2023
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 11 (19) , 4612-4624
Abstract
Metabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardio vascular disease. To evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome. This was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota. There was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated. There were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.Keywords
This publication has 46 references indexed in Scilit:
- Richness of human gut microbiome correlates with metabolic markersNature, 2013
- The SILVA ribosomal RNA gene database project: improved data processing and web-based toolsNucleic Acids Research, 2012
- Diversity, stability and resilience of the human gut microbiotaNature, 2012
- A Review of: “Fundamentals of Biostatistics, 7th ed., by B. Rosner”Journal of Biopharmaceutical Statistics, 2011
- UCHIME improves sensitivity and speed of chimera detectionBioinformatics, 2011
- Stable and bias-corrected estimation for nonparametric regression modelsJournal of Nonparametric Statistics, 2008
- Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes FederationDiabetic Medicine, 2006
- Neurologic syndrome2005
- UniFrac: a New Phylogenetic Method for Comparing Microbial CommunitiesApplied and Environmental Microbiology, 2005
- Obesity alters gut microbial ecologyProceedings of the National Academy of Sciences of the United States of America, 2005